Search

Your search keyword '"Voutsinas, Jenna"' showing total 329 results

Search Constraints

Start Over You searched for: Author "Voutsinas, Jenna" Remove constraint Author: "Voutsinas, Jenna"
329 results on '"Voutsinas, Jenna"'

Search Results

1. Cancer survivorship care for young adults: a risk-stratified, multicenter randomized controlled trial to improve symptoms

2. Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

3. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

4. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

5. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

7. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

8. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

9. Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).

14. Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study

15. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

16. Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy

17. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

19. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

22. Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

23. Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma

24. Pembrolizumab with R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy and Safety with Long-Term Follow-Up

27. Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci

28. Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor‐T cell therapy.

32. Data from HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

33. Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

38. Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

39. Polatuzumab vedotin with infusional chemotherapy (Pola-DA-EPCH-R) for untreated aggressive B-cell non-Hodgkin lymphomas

40. Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

41. Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat

42. Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

43. Impact of Hematopoietic Cell Transplantation after CAR T-Cell Therapy for B-ALL: Comparison of Statistical Models and Survival Curves By a Novel R Shiny Tool

44. Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume

45. 19 Peripheral lymphocytes and lactate dehydrogenase correlate with improved response and survival in head and neck cancer treated with immune checkpoint inhibitors

46. Socioeconomic factors and outcomes among patients with recurrent/metastatic head and neck cancer receiving immunotherapy.

47. T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume

48. Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma

Catalog

Books, media, physical & digital resources